Khoja Sheraz, Asatryan Liana, Jakowec Michael W, Davies Daryl L
Titus Family Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, Los Angeles, CA, United States.
Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
Front Cell Neurosci. 2019 Jul 23;13:331. doi: 10.3389/fncel.2019.00331. eCollection 2019.
Sensorimotor gating refers to the ability to filter incoming sensory information in a stimulus-laden environment and disruption of this physiological process has been documented in psychiatric disorders characterized by cognitive aberrations. The effectiveness of current pharmacotherapies for treatment of sensorimotor gating deficits in the patient population still remains controversial. These challenges emphasize the need to better understand the biological underpinnings of sensorimotor gating which could lead to discovery of novel drug targets for therapeutic intervention. Notably, we recently reported a role for purinergic P2X4 receptors (P2X4Rs) in regulation of sensorimotor gating using prepulse inhibition (PPI) of acoustic startle reflex. P2X4Rs are ion channels gated by adenosine-5'-triphosphate (ATP). Ivermectin (IVM) induced PPI deficits in C57BL/6J mice in a P2X4R-specific manner. Furthermore, mice deficient in P2X4Rs [P2X4R knockout (KO)] exhibited PPI deficits that were alleviated by dopamine (DA) receptor antagonists demonstrating an interaction between P2X4Rs and DA receptors in PPI regulation. On the basis of these findings, we hypothesized that increased DA neurotransmission underlies IVM-mediated PPI deficits. To test this hypothesis, we measured the effects of D1 and D2 receptor antagonists, SCH 23390 and raclopride respectively and D1 agonist, SKF 82958 on IVM-mediated PPI deficits. To gain mechanistic insights, we investigated the interaction between IVM and dopaminergic drugs on signaling molecules linked to PPI regulation in the ventral striatum. SCH 23390 significantly attenuated the PPI disruptive effects of IVM to a much greater degree than that of raclopride. SKF 82958 failed to potentiate IVM-mediated PPI disruption. At the molecular level, modulation of D1 receptors altered IVM's effects on dopamine and cyclic-AMP regulated phosphoprotein of 32 kDa (DARPP-32) phosphorylation. Additionally, IVM interacted with the DA receptors antagonists and SKF 82958 in phosphorylation of Ca/calmodulin kinase IIα (CaMKIIα) and its downstream target, neuronal nitric oxide synthase (nNOS). Current findings suggest an involvement for D1 and D2 receptors in IVM-mediated PPI disruption via modulation of DARPP-32, CaMKIIα and nNOS. Taken together, the findings suggest that stimulation of P2X4Rs can lead to DA hyperactivity and disruption of information processing, implicating P2X4Rs as a novel drug target for treatment of psychiatric disorders characterized by sensorimotor gating deficits.
感觉运动门控是指在充满刺激的环境中过滤传入感觉信息的能力,在以认知异常为特征的精神疾病中,这一生理过程的破坏已有文献记载。目前用于治疗患者群体中感觉运动门控缺陷的药物疗法的有效性仍存在争议。这些挑战凸显了更好地理解感觉运动门控的生物学基础的必要性,这可能会导致发现用于治疗干预的新型药物靶点。值得注意的是,我们最近报道了嘌呤能P2X4受体(P2X4Rs)在使用听觉惊吓反射的前脉冲抑制(PPI)调节感觉运动门控中的作用。P2X4Rs是由三磷酸腺苷(ATP)门控的离子通道。伊维菌素(IVM)以P2X4R特异性方式诱导C57BL/6J小鼠出现PPI缺陷。此外,缺乏P2X4Rs的小鼠[P2X4R基因敲除(KO)]表现出PPI缺陷,多巴胺(DA)受体拮抗剂可减轻这种缺陷,这表明P2X4Rs与DA受体在PPI调节中存在相互作用。基于这些发现,我们假设DA神经传递增加是IVM介导的PPI缺陷的基础。为了验证这一假设,我们分别测量了D1和D2受体拮抗剂SCH 23390和雷氯必利以及D1激动剂SKF 82958对IVM介导的PPI缺陷的影响。为了深入了解其机制,我们研究了IVM与多巴胺能药物在腹侧纹状体中与PPI调节相关的信号分子上的相互作用。SCH 23390比雷氯必利更显著地减弱了IVM对PPI的破坏作用。SKF 82958未能增强IVM介导的PPI破坏。在分子水平上,D1受体的调节改变了IVM对多巴胺和32 kDa多巴胺和环磷酸腺苷调节磷酸蛋白(DARPP - 32)磷酸化的影响。此外,IVM在钙/钙调蛋白激酶IIα(CaMKIIα)及其下游靶点神经元型一氧化氮合酶(nNOS)的磷酸化方面与DA受体拮抗剂和SKF 82958相互作用。目前的研究结果表明,D1和D2受体通过调节DARPP - 32、CaMKIIα和nNOS参与IVM介导的PPI破坏。综上所述,这些发现表明刺激P2X4Rs可导致DA活性亢进和信息处理破坏,提示P2X4Rs作为治疗以感觉运动门控缺陷为特征的精神疾病的新型药物靶点。